Other

Share Repurchase Program, Remaining Authorized, Amount

Regeneron Pharmaceuticals Share Repurchase Program, Remaining Authorized, Amount decreased by 68.1% to $688.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 82.2%, from $3.87B to $688.20M.

Analysis

StatementBalance Sheet Statement
SectionOther
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ4 2015
Last reportedQ4 2025

How to read this metric

A high remaining balance indicates significant capacity for future buybacks, while a low balance suggests the program may need renewal or that capital is being deployed elsewhere.

Detailed definition

This represents the remaining dollar value of shares that the company is authorized to repurchase from the open market u...

Peer comparison

Common among mature public companies; peers typically disclose this in the equity or treasury stock notes.

Metric ID: other_stock_repurchase_program_remaining_authorized_repu_889179

Historical Data

10 periods
 Q1 '23Q2 '23Q3 '23Q1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q1 '26
Value$3.05B$2.33B$1.83B$1.23B$3.63B$2.89B$3.87B$2.81B$2.16B$688.20M
QoQ Change-23.6%-21.7%-32.5%+194.5%-20.3%+33.9%-27.4%-23.4%-68.1%
YoY Change-59.6%+55.7%+58.4%+214.2%-22.5%-25.5%-82.2%
Range$688.20M$3.87B
CAGR-48.4%
Avg YoY Growth+19.8%
Median YoY Growth-22.5%
Current Streak3 quarters decline

Share Repurchase Program, Remaining Authorized, Amount at Other Companies

Frequently Asked Questions

What is Regeneron Pharmaceuticals's share repurchase program, remaining authorized, amount?
Regeneron Pharmaceuticals (REGN) reported share repurchase program, remaining authorized, amount of $688.20M in Q1 2026.
How has Regeneron Pharmaceuticals's share repurchase program, remaining authorized, amount changed year-over-year?
Regeneron Pharmaceuticals's share repurchase program, remaining authorized, amount decreased by 82.2% year-over-year, from $3.87B to $688.20M.
What does share repurchase program, remaining authorized, amount mean?
The remaining dollar amount the company is authorized to spend on buying back its own shares.